Literature DB >> 14607791

Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction.

Ahamad Hassan1, Beverley J Hunt, Michael O'Sullivan, Rachel Bell, Reuben D'Souza, Steve Jeffery, John M Bamford, Hugh S Markus.   

Abstract

Cerebral small vessel disease (SVD) causes focal lacunar infarction and more diffuse ischaemia, referred to as leukoaraiosis. Endothelial dysfunction has been proposed as a causal mechanism in the disease. Homocysteine is toxic to endothelium. We determined whether elevated homocysteine levels and the methylene tetrahydrofolate reductase (MTHFR) C677T polymorphism are risk factors for SVD as a whole, and for two different SVD subtypes: isolated lacunar infarction and ischaemic leukoaraiosis. We also determined whether any association was mediated by endothelial dysfunction, as assessed by circulating endothelial markers. One hundred and seventy-two Caucasian patients with SVD and 172 community controls of similar age and sex were studied. Serum homocysteine measurement and MTHFR genotyping was performed. Levels of intercellular adhesion molecule 1 (ICAM1) and thrombomodulin were measured in a subgroup. Mean homocysteine levels were higher in SVD than controls [14.55 micromol/l [95% confidence interval (CI) 13.78-15.35] versus 12.01 micromol/l (95% CI 11.42-12.64), P < 0.0005]. Homocysteine was a stronger risk factor in those with ischaemic leukoaraiosis [12.92 (95% CI 4.40-37.98), P < 0.0005) per micromol increase in log homocysteine concentration (P < 0.0005)] in comparison with isolated lacunar infarction [4.22 (95% CI 1.29-13.73), P = 0.02] after controlling for both conventional risk factors and age. The MTHFR 677T allele was a risk factor only in the ischaemic leukoaraiosis group [odds ratio (OR) 2.02 (95% CI 1.31-3.1), P = 0.001]. Inclusion of the endothelial markers ICAM1 and thrombomodulin in a logistic regression model resulted in the association between homocysteine and SVD no longer being significant. In conclusion, hyperhomocysteinaemia is an independent risk factor for SVD, particularly ischaemic leukoaraiosis, and this effect may be mediated via endothelial dysfunction. Homocysteine-lowering therapy may be particularly effective in this subgroup.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607791     DOI: 10.1093/brain/awh023

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  87 in total

1.  Spontaneous isolated posterior communicating artery dissection in a young adult with hyperhomocysteinemia.

Authors:  Ian C Duncan; Johannes M Terblanché
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

2.  Treatment of leukoaraiosis.

Authors:  Gary L Schwartz; Myriam Fornage; Thomas Mosley; Stephen T Turner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-07

Review 3.  Vascular complications of cystathionine β-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide research.

Authors:  Richard S Beard; Shawn E Bearden
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-22       Impact factor: 4.733

4.  Homocysteine and leukoaraiosis: time for a clinical trial?

Authors:  S Sacco; A Carolei
Journal:  Neurol Sci       Date:  2007-10       Impact factor: 3.307

5.  Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study.

Authors:  William G Christen; Robert J Glynn; Emily Y Chew; Christine M Albert; Joann E Manson
Journal:  Arch Intern Med       Date:  2009-02-23

Review 6.  Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates.

Authors:  Jeremy D Schmahmann; Eric E Smith; Florian S Eichler; Christopher M Filley
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 7.  Small vessel disease and memory loss: what the clinician needs to know to preserve patients' brain health.

Authors:  Christian Schenk; Timothy Wuerz; Alan J Lerner
Journal:  Curr Cardiol Rep       Date:  2013-12       Impact factor: 2.931

Review 8.  Understanding the role of the perivascular space in cerebral small vessel disease.

Authors:  Rosalind Brown; Helene Benveniste; Sandra E Black; Serge Charpak; Martin Dichgans; Anne Joutel; Maiken Nedergaard; Kenneth J Smith; Berislav V Zlokovic; Joanna M Wardlaw
Journal:  Cardiovasc Res       Date:  2018-09-01       Impact factor: 10.787

9.  Role of microRNA29b in blood-brain barrier dysfunction during hyperhomocysteinemia: an epigenetic mechanism.

Authors:  Anuradha Kalani; Pradip K Kamat; Anastasia Familtseva; Pankaj Chaturvedi; Nino Muradashvili; Nithya Narayanan; Suresh C Tyagi; Neetu Tyagi
Journal:  J Cereb Blood Flow Metab       Date:  2014-05-07       Impact factor: 6.200

Review 10.  The role of genetics in stroke.

Authors:  John Francis; Senthil Raghunathan; Pradeep Khanna
Journal:  Postgrad Med J       Date:  2007-09       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.